Radioisotope Production (Indium-111)

In-111 decays by electron capture and gamma emission with a half-life of 2.8 days. It is typically produced in cyclotrons by bombarding cadmium-111 with protons. The resulting In-111 is then chemically incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of cyclotrons, cadmium-111 targets, and radiochemistry facilities. Logistical challenges include the transport and delivery of In-111 radiopharmaceuticals. Accessibility for developing countries is limited by the high cost and technical expertise required for production and handling.

In-111 production and application are well-established, with widespread use in nuclear medicine.

In-111 is a radioactive isotope that emits gamma rays, requiring careful handling and shielding to minimise radiation exposure.

While In-111 is not a proliferation concern, proper control and monitoring are necessary to prevent unauthorised access or misuse.

Traditional IAEA safeguards are not directly applicable due to the absence of fissile materials. However, monitoring and verification of the production and use of In-111 may be considered to ensure transparency and prevent misuse.